Profile - To The Moon

Ericlam

Eric

Posts · 1.03KPosts · 1.03K
Following · 0Following · 0
Followers · 0Followers · 0

- EriclamEriclam
  ·10-03
  Hi My favourite @koolgal
  365 Comment
  1
  Share
  Report
- EriclamEriclam
  ·09-19
  $BABA-W(09988)$
  674 Comment
  2
  Share
  Report
- EriclamEriclam
  ·09-08
  $Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$
  904 Comment
  2
  Share
  Report
- EriclamEriclam
  ·09-05
  $FIDUCIAN GROUP LTD(FID.AU)$
  784 Comment
  1
  Share
  Report
- EriclamEriclam
  ·08-25
  $CMS(00867)$
  1.18K Comment
  1
  Share
  Report
- EriclamEriclam
  ·08-20
  Great article, would you like to share it?
  Xpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low
  Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven
  Xpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low
  731 Comment
  1
  Share
  Report
- EriclamEriclam
  ·08-20
  Great article, would you like to share it?
  Financial Report Reveals "Healthy" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth
  As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of...
  Financial Report Reveals "Healthy" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth
  916 Comment
  1
  Share
  Report
- EriclamEriclam
  ·08-19
  $Vanguard S&P 500 ETF(VOO)$
  1.03K Comment
  1
  Share
  Report
- EriclamEriclam
  ·08-14
  $Apple(AAPL)$
  510 Comment
  1
  Share
  Report
- EriclamEriclam
  ·08-14
  $Apple(AAPL)$
  991 Comment
  1
  Share
  Report
No followers yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3559787818034959","uuid":"3559787818034959","gmtCreate":1596695020477,"gmtModify":1634349872248,"name":"Ericlam","pinyin":"ericlam","introduction":"","introductionEn":"","signature":"Eric","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"","vip":1,"status":2,"fanSize":268,"headSize":739,"tweetSize":1026,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"80.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.07%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":35,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":485087308755792,"gmtCreate":1759459855439,"gmtModify":1759461504605,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"Hi My favourite <a href=\"https://ttm.financial/U/3559581955535845\"> @koolgal </a>","listText":"Hi My favourite <a href=\"https://ttm.financial/U/3559581955535845\"> @koolgal </a>","text":"Hi My favourite @koolgal","images":[{"img":"https://community-static.tradeup.com/news/720e2d95a75429d8e9ab6b284a97e717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/485087308755792","isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":480111153767136,"gmtCreate":1758238798216,"gmtModify":1758238801822,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/09988\">$BABA-W(09988)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/09988\">$BABA-W(09988)$&nbsp;</a>&nbsp;","text":"$BABA-W(09988)$","images":[{"img":"https://community-static.tradeup.com/news/51e331263837b3741fd7e02c5bad443f","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/480111153767136","isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":476208223433544,"gmtCreate":1757289096158,"gmtModify":1757296499895,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/600276\">$Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/600276\">$Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$</a>&nbsp;","text":"$Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$","images":[{"img":"https://community-static.tradeup.com/news/0ad5f6a1cee5b95385d092aae759fdee","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/476208223433544","isVote":1,"tweetType":1,"viewCount":904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":475131775918840,"gmtCreate":1757022475995,"gmtModify":1757022638041,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FID.AU\">$FIDUCIAN GROUP LTD(FID.AU)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/FID.AU\">$FIDUCIAN GROUP LTD(FID.AU)$</a>&nbsp;","text":"$FIDUCIAN GROUP LTD(FID.AU)$","images":[{"img":"https://community-static.tradeup.com/news/248e45a8621df1c4a88657891638a9e6","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/475131775918840","isVote":1,"tweetType":1,"viewCount":784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":471234502746464,"gmtCreate":1756084841629,"gmtModify":1756084844798,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/00867\">$CMS(00867)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/00867\">$CMS(00867)$</a>&nbsp;","text":"$CMS(00867)$","images":[{"img":"https://community-static.tradeup.com/news/44c5ad08ffdae6eda34c96f9aa6e8de0","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/471234502746464","isVote":1,"tweetType":1,"viewCount":1178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":469452052877360,"gmtCreate":1755650397737,"gmtModify":1755650400212,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/469452052877360","repostId":"2560161971","repostType":4,"repost":{"id":"2560161971","kind":"live","pubTimestamp":1755614108,"share":"https://ttm.financial/m/news/2560161971?lang=&edition=fundamental","pubTime":"2025-08-19 22:35","market":"us","language":"en","title":"Xpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2560161971","media":"CnEVPost","summary":"Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven ","content":"<div>\n<p>Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven by strong growth in vehicle deliveries.XPeng’s U.S.-listed shares jumped 5% while its rival NIO ...</p>\n\n<a href=\"https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/\">Web Link</a>\n\n</div>\n","source":"cnevpost_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-19 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/><strong>CnEVPost</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven by strong growth in vehicle deliveries.XPeng’s U.S.-listed shares jumped 5% while its rival NIO ...</p>\n\n<a href=\"https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1539":"汽车股","XPEV":"小鹏汽车","09868":"小鹏汽车-W","BK1119":"汽车制造商","BK1610":"ETF&股票定投概念","BK1588":"回港中概股","LU0593848301.USD":"未来资产亚洲卓越消费股票基金A","BK1587":"次新股","BK1575":"同股不同权"},"source_url":"https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2560161971","content_text":"Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven by strong growth in vehicle deliveries.XPeng’s U.S.-listed shares jumped 5% while its rival NIO gained over 6%The company reported revenue of RMB 18.27 billion ($2.55 billion) for the second quarter, up 125.3 percent year-on-year and up 15.6 percent quarter-on-quarter, according to its unaudited financial results released today.Notably, this marks Xpeng's highest quarterly revenue on record, though it still fell slightly short of Wall Street analysts' expectations of RMB 18.38 billion.In the second quarter, Xpeng delivered a record 103,181 vehicles, within the guidance range of 102,000 to 108,000 vehicles, slightly below analysts' expectations of 105,000 vehicles.Deliveries for the quarter increased by 241.58 percent year-on-year and up 9.76 percent quarter-on-quarter.Xpeng's net loss for the second quarter was RMB 480 million, a new low since the third quarter of 2020, representing a year-on-year decrease of 62.81 percent and a quarter-on-quarter decrease of 28.05 percent.Under non-GAAP, adjusted net loss for the second quarter was RMB 390 million, compared to RMB 1.22 billion in the same period of 2024 and RMB 430 million in the first quarter of 2025.Xpeng's second-quarter revenues from vehicle sales was RMB 16.88 billion, up 147.6 percent year-on-year and up 17.5 percent quarter-on-quarter, primarily driven by increased vehicle deliveries.Its second-quarter service and other revenue was RMB 1.39 billion, up 7.6 percent year-on-year but down 3.5 percent quarter-on-quarter.The year-on-year increase was primarily attributable to growth in revenue from parts and accessories sales as cumulative vehicle sales increased. The quarter-on-quarter decrease was primarily attributable to fluctuations in revenue from technology R&D services, Xpeng said.The company's gross margin for the second quarter was a record 17.3 percent, compared to 14.0 percent in the same period of 2024 and 15.6 percent in the first quarter.Xpeng reports record quarterly revenue, net loss narrows to 5-year lowThe second-quarter vehicle margin reached a record 14.3 percent, compared to 6.4 percent in the same period of 2024 and 10.5 percent in the first quarter of 2025. These increases were primarily attributed to ongoing cost reductions and optimization of the vehicle model product mix, according to Xpeng.Xpeng reports record quarterly revenue, net loss narrows to 5-year lowThe company's service and others margin for the second quarter was 53.6 percent, compared to 54.3 percent in the same period of 2024 and 66.4 percent in the first quarter. The sequential decline was primarily due to fluctuations related to technology R&D services.The company's R&D expenses for the second quarter were RMB 2.21 billion, up 50.4 percent year-on-year and up 11.4 percent quarter-on-quarter, mainly due to increased expenses related to new vehicle models and technology development.Sales, general and administrative expenses for the second quarter were RMB 2.17 billion, up 37.7 percent year-on-year and up 11.4 percent quarter-on-quarter. This was mainly due to increased franchisee commissions, marketing and advertising expenses.As of June 30, 2025, the company held cash and cash equivalents, restricted cash, short-term investments, and time deposits totaling RMB 47.57 billion, compared to RMB 41.96 billion as of December 31, 2025.Xpeng guided third-quarter vehicle deliveries to be between 113,000 and 118,000 units, representing a year-on-year increase of about 142.8 percent to 153.6 percent.This guidance implies that Xpeng expects to deliver a cumulative total of 76,283 to 81,283 vehicles in August and September, considering the 36,717 vehicles delivered in July.The company guided third-quarter revenue to be between RMB 19.6 billion and RMB 21.0 billion, representing a year-on-year increase of about 94.0 percent to 107.9 percent.","news_type":1,"symbols_score_info":{"09868":0.9,"XPEV":1.1}},"isVote":1,"tweetType":1,"viewCount":731,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":469405530288168,"gmtCreate":1755650306356,"gmtModify":1755650308601,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/469405530288168","repostId":"1116300138","repostType":2,"repost":{"id":"1116300138","kind":"news","weMediaInfo":{"introduction":"Global Stock Market Deep Analysis","home_visible":1,"media_name":"Deep News","id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"pubTimestamp":1755612253,"share":"https://ttm.financial/m/news/1116300138?lang=&edition=fundamental","pubTime":"2025-08-19 22:04","market":"sh","language":"en","title":"Financial Report Reveals \"Healthy\" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1116300138","media":"Deep News","summary":"As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of...","content":"<p>As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of business operations, while focusing on enhancing medical service capabilities, particularly building integrated online and offline service systems and complete service loops.</p>\n<p>In JD Health's underlying business logic, empowering partners represents a crucial component, making collaborative growth with partners one of JD Health's long-term strategies. Business-related dynamic events serve as important windows for investors to observe how JD Health advances its long-term strategy.</p>\n<p>On August 15, the day after announcing its interim results, JD Health reached a strategic cooperation agreement with Eisai China. Through this partnership, Lemborexant (brand name: Dayvigo), an insomnia treatment drug developed by Eisai China, will launch exclusively online through JD Health following regulatory approval. Lemborexant represents China's first non-sedating anti-insomnia new drug, potentially reshaping the anti-insomnia pharmaceutical market.</p>\n<p>This development aligns with strengthening supply chain advantages and corresponds to JD Health's core long-term development direction. The interim financial report released on August 14 showed that over 30 innovative drugs launched online through JD Health in the first half of this year, alongside collaborations with multiple medical device and nutritional health brands, achieving online debuts for numerous products across the entire network.</p>\n<p>These developments confirm JD Health's efforts to further consolidate its core competitive advantages: supply chain capabilities and brand empowerment value. The synergy between these elements has facilitated extensive collaborations, creating advantages in debut product quantities beyond the existing advantages in pharmaceutical and health product category numbers.</p>\n<p>**Service Model Innovation Becomes Second Growth Curve**</p>\n<p>In recent years, a core trend in the digital medical industry has been online-offline integration. Major players are refining traditional online channel capabilities while prioritizing the fusion of online and offline services and complete connectivity across the entire chain.</p>\n<p>For internet medical companies like JD Health, the main business includes pharmaceutical retail and medical services. The business core integrates these two major segments, creating a complete \"medical testing, diagnosis, and medication\" service loop. Internet hospitals serve as key components in this service loop, with their service capabilities in various disease specialties directly determining service depth and breadth.</p>\n<p>Through long-term development, JD Health has effectively explored internet medical specialty service models in five major areas: dermatology, mental health, traditional Chinese medicine, oncology, and men's health.</p>\n<p>As a new-type medical health service enterprise, JD Health focuses on deepening and specializing online services while emphasizing \"home delivery\" capabilities for offline services. Examples include nurse home visits and home rapid testing services, with service levels primarily reflected in \"breadth\" and \"speed.\"</p>\n<p>\"Breadth\" refers to nurse home visit services expanding to 7 categories and 64 items, while home rapid testing currently provides over 160 rapid testing services. \"Speed\" means nurse home visits can achieve order acceptance in as fast as 3 minutes and door-to-door service within 1 hour.</p>\n<p>These service capabilities demonstrate their value in specific demand scenarios. Taking flu as an example, during flu season, users can quickly determine flu types through JD Health's home rapid testing service, with subsequent consultations, medication purchases, and follow-ups completed online, typically finishing the entire process within one day.</p>\n<p>**Weight Management Business Layout Demonstrates Strategic Extension**</p>\n<p>JD Health's weight management business layout represents both an extension of existing business strategy and a typical case of multi-win outcomes. This year, weight management has become a nationally discussed topic, driven by continuously growing obesity populations and sustained strong demand, alongside GLP-1 drugs like semaglutide expanding into weight loss indications, reshaping the weight loss drug market and accelerating market growth.</p>\n<p>Based on current market expectations, GLP-1 drugs with weight loss indications could reach trillion-scale market potential. JD Health's related business layout includes strategic cooperation with Novo Nordisk, the original developer of semaglutide. Mazdutide (brand name: Xinermei) from Innovent Biologics launched exclusively on JD Health immediately after approval, with search volume for \"Xinermei\" exceeding one million on the JD platform between July 4 and August 4, serving over 30,000 users.</p>\n<p>**User Growth and Stickiness Drive Performance Improvement**</p>\n<p>JD Health's 2025 interim financial report shows revenue of 35.3 billion yuan in the first half of 2025, representing 24.5% year-over-year growth, not only exceeding market expectations but achieving the strongest half-year growth rate since the end of the pandemic in 2023. Operationally, active users exceeded 200 million by the first half of 2025, achieving a milestone breakthrough.</p>\n<p>The core highlights of JD Health's financial report are revenue growth and attribution for pharmaceutical e-commerce and medical services, the two main businesses. Pharmaceutical e-commerce has maintained revenue proportions above 83% in recent years, serving as the company's performance foundation, achieving 29.3 billion yuan revenue in the first half of 2025, up 23% year-over-year.</p>\n<p>Medical services have shown stronger growth momentum than pharmaceutical e-commerce in recent years, serving as an important marginal force driving company performance growth, with first-half revenue of 6 billion yuan, up 34% year-over-year.</p>\n<p>Pharmaceutical e-commerce revenue growth primarily benefits from active user growth and increased per-user purchase amounts, essentially reflecting how supply chain and service capabilities support continuous product category enrichment and complete service loop experience optimization, creating positive resonance with JD Health's brand value and improving user mindshare and online sales penetration during the reporting period.</p>\n<p>**AI Upgrade Provides Important Valuation Support**</p>\n<p>Following the financial report release, investors responded positively to JD Health's performance, with the company's stock price surging 21% cumulatively over two trading days on August 15 and 18. Particularly on August 15, the day after the financial report release, intraday gains exceeded 16% at their peak, ultimately closing up 12%.</p>\n<p>JD Health's post-earnings stock surge stems partly from market recognition of its performance and underlying business model. Leveraging supply chain advantages, JD Health has built an integrated \"supply chain + service + technology\" ecosystem and complete \"medical testing, diagnosis, and medication\" service loop, creating significant differentiation from peers and demonstrating considerable scarcity value in capital markets due to its difficult-to-replicate characteristics.</p>\n<p>Another factor is investor response to JD Health's strong AI concept attributes. According to this quarter's financial report, JD Health launched the \"AI Jingyi\" product series in the first half of this year, covering multi-role professional service intelligent agents for users, including AI doctors, AI pharmacists, and AI psychological counselors, along with digital avatars and AI assistants for doctors. During the reporting period, \"AI Jingyi\" served over 50 million users cumulatively.</p>\n<p>For hospital AI upgrades, JD Health introduced its first hospital full-scenario product \"JD Zhuoyi,\" primarily providing AI upgrades for three main \"entities\": individual users, doctors, and hospital operations management. This has been implemented in multiple medical institutions, such as the AI-driven outpatient patient service process loop created through JD Health's collaboration with the First Affiliated Hospital of Wenzhou Medical University, which has served over 2.2 million patient visits.</p>\n<p>Currently, AI field attention has shifted toward applications, and JD Health, as an important industry participant, has continuously focused on application-level development in AI upgrades in recent years, aligning with industry trends while achieving significant results.</p>\n<p>Long-term, JD Health's continued investment and innovation in AI may break through traditional internet medical enterprise growth bottlenecks, with AI's role as a third growth curve becoming increasingly prominent, helping the company improve valuation levels in capital markets.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Financial Report Reveals \"Healthy\" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFinancial Report Reveals \"Healthy\" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-08-19 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of business operations, while focusing on enhancing medical service capabilities, particularly building integrated online and offline service systems and complete service loops.</p>\n<p>In JD Health's underlying business logic, empowering partners represents a crucial component, making collaborative growth with partners one of JD Health's long-term strategies. Business-related dynamic events serve as important windows for investors to observe how JD Health advances its long-term strategy.</p>\n<p>On August 15, the day after announcing its interim results, JD Health reached a strategic cooperation agreement with Eisai China. Through this partnership, Lemborexant (brand name: Dayvigo), an insomnia treatment drug developed by Eisai China, will launch exclusively online through JD Health following regulatory approval. Lemborexant represents China's first non-sedating anti-insomnia new drug, potentially reshaping the anti-insomnia pharmaceutical market.</p>\n<p>This development aligns with strengthening supply chain advantages and corresponds to JD Health's core long-term development direction. The interim financial report released on August 14 showed that over 30 innovative drugs launched online through JD Health in the first half of this year, alongside collaborations with multiple medical device and nutritional health brands, achieving online debuts for numerous products across the entire network.</p>\n<p>These developments confirm JD Health's efforts to further consolidate its core competitive advantages: supply chain capabilities and brand empowerment value. The synergy between these elements has facilitated extensive collaborations, creating advantages in debut product quantities beyond the existing advantages in pharmaceutical and health product category numbers.</p>\n<p>**Service Model Innovation Becomes Second Growth Curve**</p>\n<p>In recent years, a core trend in the digital medical industry has been online-offline integration. Major players are refining traditional online channel capabilities while prioritizing the fusion of online and offline services and complete connectivity across the entire chain.</p>\n<p>For internet medical companies like JD Health, the main business includes pharmaceutical retail and medical services. The business core integrates these two major segments, creating a complete \"medical testing, diagnosis, and medication\" service loop. Internet hospitals serve as key components in this service loop, with their service capabilities in various disease specialties directly determining service depth and breadth.</p>\n<p>Through long-term development, JD Health has effectively explored internet medical specialty service models in five major areas: dermatology, mental health, traditional Chinese medicine, oncology, and men's health.</p>\n<p>As a new-type medical health service enterprise, JD Health focuses on deepening and specializing online services while emphasizing \"home delivery\" capabilities for offline services. Examples include nurse home visits and home rapid testing services, with service levels primarily reflected in \"breadth\" and \"speed.\"</p>\n<p>\"Breadth\" refers to nurse home visit services expanding to 7 categories and 64 items, while home rapid testing currently provides over 160 rapid testing services. \"Speed\" means nurse home visits can achieve order acceptance in as fast as 3 minutes and door-to-door service within 1 hour.</p>\n<p>These service capabilities demonstrate their value in specific demand scenarios. Taking flu as an example, during flu season, users can quickly determine flu types through JD Health's home rapid testing service, with subsequent consultations, medication purchases, and follow-ups completed online, typically finishing the entire process within one day.</p>\n<p>**Weight Management Business Layout Demonstrates Strategic Extension**</p>\n<p>JD Health's weight management business layout represents both an extension of existing business strategy and a typical case of multi-win outcomes. This year, weight management has become a nationally discussed topic, driven by continuously growing obesity populations and sustained strong demand, alongside GLP-1 drugs like semaglutide expanding into weight loss indications, reshaping the weight loss drug market and accelerating market growth.</p>\n<p>Based on current market expectations, GLP-1 drugs with weight loss indications could reach trillion-scale market potential. JD Health's related business layout includes strategic cooperation with Novo Nordisk, the original developer of semaglutide. Mazdutide (brand name: Xinermei) from Innovent Biologics launched exclusively on JD Health immediately after approval, with search volume for \"Xinermei\" exceeding one million on the JD platform between July 4 and August 4, serving over 30,000 users.</p>\n<p>**User Growth and Stickiness Drive Performance Improvement**</p>\n<p>JD Health's 2025 interim financial report shows revenue of 35.3 billion yuan in the first half of 2025, representing 24.5% year-over-year growth, not only exceeding market expectations but achieving the strongest half-year growth rate since the end of the pandemic in 2023. Operationally, active users exceeded 200 million by the first half of 2025, achieving a milestone breakthrough.</p>\n<p>The core highlights of JD Health's financial report are revenue growth and attribution for pharmaceutical e-commerce and medical services, the two main businesses. Pharmaceutical e-commerce has maintained revenue proportions above 83% in recent years, serving as the company's performance foundation, achieving 29.3 billion yuan revenue in the first half of 2025, up 23% year-over-year.</p>\n<p>Medical services have shown stronger growth momentum than pharmaceutical e-commerce in recent years, serving as an important marginal force driving company performance growth, with first-half revenue of 6 billion yuan, up 34% year-over-year.</p>\n<p>Pharmaceutical e-commerce revenue growth primarily benefits from active user growth and increased per-user purchase amounts, essentially reflecting how supply chain and service capabilities support continuous product category enrichment and complete service loop experience optimization, creating positive resonance with JD Health's brand value and improving user mindshare and online sales penetration during the reporting period.</p>\n<p>**AI Upgrade Provides Important Valuation Support**</p>\n<p>Following the financial report release, investors responded positively to JD Health's performance, with the company's stock price surging 21% cumulatively over two trading days on August 15 and 18. Particularly on August 15, the day after the financial report release, intraday gains exceeded 16% at their peak, ultimately closing up 12%.</p>\n<p>JD Health's post-earnings stock surge stems partly from market recognition of its performance and underlying business model. Leveraging supply chain advantages, JD Health has built an integrated \"supply chain + service + technology\" ecosystem and complete \"medical testing, diagnosis, and medication\" service loop, creating significant differentiation from peers and demonstrating considerable scarcity value in capital markets due to its difficult-to-replicate characteristics.</p>\n<p>Another factor is investor response to JD Health's strong AI concept attributes. According to this quarter's financial report, JD Health launched the \"AI Jingyi\" product series in the first half of this year, covering multi-role professional service intelligent agents for users, including AI doctors, AI pharmacists, and AI psychological counselors, along with digital avatars and AI assistants for doctors. During the reporting period, \"AI Jingyi\" served over 50 million users cumulatively.</p>\n<p>For hospital AI upgrades, JD Health introduced its first hospital full-scenario product \"JD Zhuoyi,\" primarily providing AI upgrades for three main \"entities\": individual users, doctors, and hospital operations management. This has been implemented in multiple medical institutions, such as the AI-driven outpatient patient service process loop created through JD Health's collaboration with the First Affiliated Hospital of Wenzhou Medical University, which has served over 2.2 million patient visits.</p>\n<p>Currently, AI field attention has shifted toward applications, and JD Health, as an important industry participant, has continuously focused on application-level development in AI upgrades in recent years, aligning with industry trends while achieving significant results.</p>\n<p>Long-term, JD Health's continued investment and innovation in AI may break through traditional internet medical enterprise growth bottlenecks, with AI's role as a third growth curve becoming increasingly prominent, helping the company improve valuation levels in capital markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"86618":"京东健康-R","BK1571":"互联网医疗","BK1589":"北水核心资产","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","06618":"京东健康","BK1515":"抗疫概念","LU0051755006.USD":"摩根大通中国A (dist)","BK1591":"就地过年概念","BK1142":"互联网与直销零售","BK1615":"港股-互联网","BK1247":"药品零售","BK1583":"高瓴概念"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116300138","content_text":"As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of business operations, while focusing on enhancing medical service capabilities, particularly building integrated online and offline service systems and complete service loops.\nIn JD Health's underlying business logic, empowering partners represents a crucial component, making collaborative growth with partners one of JD Health's long-term strategies. Business-related dynamic events serve as important windows for investors to observe how JD Health advances its long-term strategy.\nOn August 15, the day after announcing its interim results, JD Health reached a strategic cooperation agreement with Eisai China. Through this partnership, Lemborexant (brand name: Dayvigo), an insomnia treatment drug developed by Eisai China, will launch exclusively online through JD Health following regulatory approval. Lemborexant represents China's first non-sedating anti-insomnia new drug, potentially reshaping the anti-insomnia pharmaceutical market.\nThis development aligns with strengthening supply chain advantages and corresponds to JD Health's core long-term development direction. The interim financial report released on August 14 showed that over 30 innovative drugs launched online through JD Health in the first half of this year, alongside collaborations with multiple medical device and nutritional health brands, achieving online debuts for numerous products across the entire network.\nThese developments confirm JD Health's efforts to further consolidate its core competitive advantages: supply chain capabilities and brand empowerment value. The synergy between these elements has facilitated extensive collaborations, creating advantages in debut product quantities beyond the existing advantages in pharmaceutical and health product category numbers.\n**Service Model Innovation Becomes Second Growth Curve**\nIn recent years, a core trend in the digital medical industry has been online-offline integration. Major players are refining traditional online channel capabilities while prioritizing the fusion of online and offline services and complete connectivity across the entire chain.\nFor internet medical companies like JD Health, the main business includes pharmaceutical retail and medical services. The business core integrates these two major segments, creating a complete \"medical testing, diagnosis, and medication\" service loop. Internet hospitals serve as key components in this service loop, with their service capabilities in various disease specialties directly determining service depth and breadth.\nThrough long-term development, JD Health has effectively explored internet medical specialty service models in five major areas: dermatology, mental health, traditional Chinese medicine, oncology, and men's health.\nAs a new-type medical health service enterprise, JD Health focuses on deepening and specializing online services while emphasizing \"home delivery\" capabilities for offline services. Examples include nurse home visits and home rapid testing services, with service levels primarily reflected in \"breadth\" and \"speed.\"\n\"Breadth\" refers to nurse home visit services expanding to 7 categories and 64 items, while home rapid testing currently provides over 160 rapid testing services. \"Speed\" means nurse home visits can achieve order acceptance in as fast as 3 minutes and door-to-door service within 1 hour.\nThese service capabilities demonstrate their value in specific demand scenarios. Taking flu as an example, during flu season, users can quickly determine flu types through JD Health's home rapid testing service, with subsequent consultations, medication purchases, and follow-ups completed online, typically finishing the entire process within one day.\n**Weight Management Business Layout Demonstrates Strategic Extension**\nJD Health's weight management business layout represents both an extension of existing business strategy and a typical case of multi-win outcomes. This year, weight management has become a nationally discussed topic, driven by continuously growing obesity populations and sustained strong demand, alongside GLP-1 drugs like semaglutide expanding into weight loss indications, reshaping the weight loss drug market and accelerating market growth.\nBased on current market expectations, GLP-1 drugs with weight loss indications could reach trillion-scale market potential. JD Health's related business layout includes strategic cooperation with Novo Nordisk, the original developer of semaglutide. Mazdutide (brand name: Xinermei) from Innovent Biologics launched exclusively on JD Health immediately after approval, with search volume for \"Xinermei\" exceeding one million on the JD platform between July 4 and August 4, serving over 30,000 users.\n**User Growth and Stickiness Drive Performance Improvement**\nJD Health's 2025 interim financial report shows revenue of 35.3 billion yuan in the first half of 2025, representing 24.5% year-over-year growth, not only exceeding market expectations but achieving the strongest half-year growth rate since the end of the pandemic in 2023. Operationally, active users exceeded 200 million by the first half of 2025, achieving a milestone breakthrough.\nThe core highlights of JD Health's financial report are revenue growth and attribution for pharmaceutical e-commerce and medical services, the two main businesses. Pharmaceutical e-commerce has maintained revenue proportions above 83% in recent years, serving as the company's performance foundation, achieving 29.3 billion yuan revenue in the first half of 2025, up 23% year-over-year.\nMedical services have shown stronger growth momentum than pharmaceutical e-commerce in recent years, serving as an important marginal force driving company performance growth, with first-half revenue of 6 billion yuan, up 34% year-over-year.\nPharmaceutical e-commerce revenue growth primarily benefits from active user growth and increased per-user purchase amounts, essentially reflecting how supply chain and service capabilities support continuous product category enrichment and complete service loop experience optimization, creating positive resonance with JD Health's brand value and improving user mindshare and online sales penetration during the reporting period.\n**AI Upgrade Provides Important Valuation Support**\nFollowing the financial report release, investors responded positively to JD Health's performance, with the company's stock price surging 21% cumulatively over two trading days on August 15 and 18. Particularly on August 15, the day after the financial report release, intraday gains exceeded 16% at their peak, ultimately closing up 12%.\nJD Health's post-earnings stock surge stems partly from market recognition of its performance and underlying business model. Leveraging supply chain advantages, JD Health has built an integrated \"supply chain + service + technology\" ecosystem and complete \"medical testing, diagnosis, and medication\" service loop, creating significant differentiation from peers and demonstrating considerable scarcity value in capital markets due to its difficult-to-replicate characteristics.\nAnother factor is investor response to JD Health's strong AI concept attributes. According to this quarter's financial report, JD Health launched the \"AI Jingyi\" product series in the first half of this year, covering multi-role professional service intelligent agents for users, including AI doctors, AI pharmacists, and AI psychological counselors, along with digital avatars and AI assistants for doctors. During the reporting period, \"AI Jingyi\" served over 50 million users cumulatively.\nFor hospital AI upgrades, JD Health introduced its first hospital full-scenario product \"JD Zhuoyi,\" primarily providing AI upgrades for three main \"entities\": individual users, doctors, and hospital operations management. This has been implemented in multiple medical institutions, such as the AI-driven outpatient patient service process loop created through JD Health's collaboration with the First Affiliated Hospital of Wenzhou Medical University, which has served over 2.2 million patient visits.\nCurrently, AI field attention has shifted toward applications, and JD Health, as an important industry participant, has continuously focused on application-level development in AI upgrades in recent years, aligning with industry trends while achieving significant results.\nLong-term, JD Health's continued investment and innovation in AI may break through traditional internet medical enterprise growth bottlenecks, with AI's role as a third growth curve becoming increasingly prominent, helping the company improve valuation levels in capital markets.","news_type":1,"symbols_score_info":{"86618":1,"06618":1}},"isVote":1,"tweetType":1,"viewCount":916,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":469094972682488,"gmtCreate":1755563222160,"gmtModify":1755563225370,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","text":"$Vanguard S&P 500 ETF(VOO)$","images":[{"img":"https://community-static.tradeup.com/news/dfc55a21543d084bf21a1eba482048ce","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/469094972682488","isVote":1,"tweetType":1,"viewCount":1031,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":467325755576760,"gmtCreate":1755130860018,"gmtModify":1755130862916,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/dae3476fea5fc10b72d58b8b033966d7","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/467325755576760","isVote":1,"tweetType":1,"viewCount":510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":467325531677376,"gmtCreate":1755130806244,"gmtModify":1755130810649,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559787818034959","idStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/cc47221296177fb1ef93ffc942e187be","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/467325531677376","isVote":1,"tweetType":1,"viewCount":991,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}